- Datum03.07.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Aclaris Therapeutics Inc. Aktie
Verkaufen
Kaufen
Aclaris Therapeutics Inc. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Aclaris Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
3,57 %
Intraday
-7,05 %
1 Woche
-1,36 %
1 Monat
-41,53 %
Seit Jahresbeginn
26,09 %
1 Jahr
-89,52 %
3 Jahre
-3,33 %
5 Jahre
Passender Service zu Aclaris Therapeutics Inc.
Webinar zu Aclaris Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,050-5,170
- Jahrestief / Hoch ($)1,050-2,795
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Aclaris Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Aclaris Therapeutics Inc.
- Aug6Aclaris Therapeutics Inc.Q2 2025 Earnings Release
- Nov5Aclaris Therapeutics Inc.Q3 2025 Earnings Release
- Mär3Aclaris Therapeutics Inc.Q4 2025 Earnings Release
Beschreibung
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
